Hemoglobinopathy and pediatrics in the time of covid-19
Fecha
2020Autor
Souza Vilela, Thiago de
Pellegrini Braga, Josefina Aparecida
Loggetto, Sandra Regina
Resumen
Introduction: It is important to know if patients with hemoglobinopathy could be more susceptible to COVID-19.
Objective: Analyze SARS-CoV-2 infection in pediatric patients with hemoglobinopathy.
Methods: Using the online platforms LILACS, PUBMED and EMBASE, on 17- JUL-2020 a search
was made for the terms COVID-19 and SARS-CoV-2 associated with “sickle cell”, “thalassemia” and “hemoglobinopathy”.
Results: There were 623 pediatric and adult patients with sickle cell disease (SCD) or beta
thalassemia (BT) and COVID-19. Total mortality rate was 6.42%. No pediatric patient with
BT has been described. So, our analysis focused on children and adolescents with SCD:
there were 121 pediatric patients, one adolescent died, prophylactic anticoagulation was
prescribed to six patients, 11.76% needed intensive care unit, blood transfusion was prescribed in 29.70%. Vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) were the
main clinical manifestations in SCD.
Discussion: Pediatric patients with SCD and COVID-19 have a low mortality rate when compared to adults, although is higher than the global pediatric population with COVID-19
(0−0.67%). The comorbidities associated with age and the long-term complications inherent
to hemoglobinopathies may contribute to the increased mortality outside the pediatric age
group. In SCD the clinical manifestations, both in children and adults, are VOC and ACS, and
there was increase in blood requirement. Pediatric SCD patients with COVID-19 need more
intensive care unit than the global pediatric population (3.30%).
Conclusion: Despite pediatric population with SCD needs more intensive care, the outcome
after infection by COVID-19 is favorable
Palabras clave
Children; Coronavirus; Sickle cell; Thalassemia; SARS-CoV-2Enlace al recurso
https://doi.org/10.1016/j.htct.2020.11.002Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.